Inherently Controlled Magnetic Bearing Rotary Blood Pump

描述(由申请人提供)：本二期项目的目标是 演示一种完全可植入的旋转脑室辅助装置的原型 设备(VAD)。该泵采用了先进的三维磁力泵 第一阶段演示了转子的悬架。此轴承系统 既不需要位置传感器，也不需要主动反馈电子设备，从而 适用于血泵的最简单的3-0磁悬浮轴承。轴承线圈 构成调谐电感-电容-电阻(LCR)电路的一部分。正弦 波发生器为线圈供电。转子的运动改变了电感和 因此，调整电路以使电流流量发生变化 总是出现与运动方向相反的情况。转子位置的控制 是固有的轴承结构和伊姆肖？S定律是满意的。第一阶段 证明了这种承载结构可以动态稳定、低成本地 功率消耗，并具有足够的硬度以应对外部冲击和 振动载荷。在第二阶段，该计划将进入设计和 开发可植入旋转式VAD和电子封装的原型并执行 体内试验和体外耐力试验。成功完成后将引领 直接进入Ill阶段的努力，并最终获得FDA批准进行临床试验。 拟议的商业应用：心脏病仍然是美国死亡和残疾的主要原因。在每年死于心脏相关问题的60万美国人中，大约有3万到6万人可能会通过心脏移植获救。然而，供体心脏的短缺阻碍了这一点，并刺激了许多机械心脏辅助和替代装置的发展。如果证明机械辅助泵足够安全可靠，改善心脏受损患者生活质量的潜在用途将极大地扩大市场。

Description (provided by applicant): The goal of this Phase II project is to demonstrate the prototype of a fully implantable rotary ventricular assist device (VAD). This pump utilizes the advanced three-dimensional magnetic suspension for the rotor demonstrated during Phase I. This bearing system requires neither position sensors nor active feedback electronics, resulting in the simplest 3-0 magnetic bearing available for blood pumps. The bearing coils form part of a tuned inductance-capacitance-resistance (LCR) circuit. A sine wave generator powers the coil. Motion of the rotor varies the inductance and therefore tuning of the circuit such that changes in electrical current flow always occur to oppose the direction of motion. Control of the rotor position is inherent in the bearing construction and Eamshaw?s Law is satisfied. Phase I demonstrated that this bearing construct can be dynamically stable, low in power consumption, and adequately stiff to handle externally applied shock and vibration loads. During Phase II, the program will advance to design and develop a prototype implantable rotary VAD and electronics package and perform in-vivo tests and in-vitro endurance tests. Successful completion will lead directly to a Phase Ill effort and ultimately FDA approval for clinical trials. PROPOSED COMMERCIAL APPLICATION: Heart disease remains the leading cause of death and disability in the United States. Of the 600,000 Americans who die each year due to heart-related problems, about 30,000 to 60,000 could probably be saved with heart transplants. However, the shortage of donor hearts precludes this, and has stimulated the development of many mechanical heart assist and replacement devices. Should mechanical assist pumps prove sufficiently safe and reliable, the potential use to improve the quality of life for cardiac-impaired patients dramatically expands the market.